Kyle Diamantas

Americans are increasingly using peptide compounds for health and performance from unregulated sources, creating risks. The FDA, led by Kyle Diamantas, has an opportunity to regulate peptides without resorting to a crackdown or uncontrolled access.

Pfizer disclosed that its experimental lung cancer drug, sigvotatug vedotin, failed to show a statistically significant improvement over docetaxel in a clinical trial. The U.S. Food and Drug Administration announced a pilot program to accelerate early-stage clinical trials, aiming to reduce development timelines and counter Chinese dominance in the field.

Eli Lilly is reducing its $2.67 billion investment in Germany's weight-loss syringe production due to new cost-cutting laws, and Boehringer Ingelheim is cutting $1 billion in German investments amid sector uncertainty. U.S. FDA Acting Commissioner Kyle Diamantas is engaging rare disease groups to address concerns raised by his predecessor's policies.

Eli Lilly is threatening to cut off price discounts from 340B hospitals that fail to submit required claims data, aiming to prevent duplicate discounts. The FDA is set to hold a closed-door meeting with rare disease advocates to discuss regulatory challenges for drug approvals.

Kyle Diamantas, a Florida attorney with no public health experience, was appointed as the FDA's top food official by the Trump administration in 2025. Despite his background representing food and beverage industry clients at Jones Day, his lack of science, medicine, or government experience raised skepticism. He assumed leadership amid FDA turmoil, including DOGE layoffs and the resignation of former leader Jim Jones.

Parabilis Medicines has filed to go public under the symbol PBLS. Former FDA commissioner David Kessler expressed confidence in Kyle Diamantas, the new interim FDA chief. The development comes amid increased competition from China in the biotech industry.

Biotech investors' concerns about the Make America Healthy Again movement are fading, and a former FDA head has confidence in the agency's new acting commissioner. The FDA has faced recent tumult, but an inflection point may be nearing. The mood among biotech investors is improving due to decreased political risk.

Former FDA commissioner David Kessler is hopeful that the agency is on a better path under newly appointed acting commissioner Kyle Diamantas. Kessler expressed confidence in Diamantas' ability to serve as a stabilizing force for the agency. The FDA has faced upheaval and high-profile exits recently.

Makary is departing and his policies are being discussed, Kyle Diamantas is his acting replacement, and FDA reporter Lizzy Lawrence is providing insight on the topic.

Kyle Diamantas is the new acting commissioner of the Food and Drug Administration, expected to bring stability to the agency. He previously served as the FDA's top food regulator. His appointment follows Marty Makary's resignation.

The pharmaceutical industry is calling for stability and predictability from the next FDA commissioner after a tumultuous period. The CEO of PhRMA, Steve Ubl, and Bristol Myers Squibb CEO Chris Boerner emphasized the need for a stable FDA to ensure certainty in drug development. The industry is also pushing back against President Trump's 'most favored nation' pricing policy.

The Trump administration is searching for a new FDA commissioner after Marty Makary's resignation, seeking someone to rebuild trust and focus on food policy and drug-approval reforms. The search process is expected to take several weeks. The Senate's schedule and other confirmations may delay the appointment.

FDA Commissioner Marty Makary resigned, with President Trump thanking him for his work. Anti-abortion groups had previously called for Makary's removal over his stance on medication abortion access. Kyle Diamantas will serve as acting commissioner.

Marty Makary is resigning as FDA commissioner and Kyle Diamantas will step in as acting commissioner. This change occurs after President Trump confirmed Makary's resignation. The news impacts the leadership of the FDA.

US Food and Drug Administration Commissioner Marty Makary is resigning, with Kyle Diamantas stepping in as acting commissioner. Eli Lilly's weight loss pill Foundayo was found to have patients regain an average of 2-11 pounds after switching from injectable medications. The FDA has been marked by personnel drama and controversy over political pressure.

Kyle Diamantas is the new acting FDA commissioner, previously serving as deputy commissioner for food at the FDA. He was described by Donald Trump as a 'very talented person'. Diamantas has a background as a corporate lawyer, defending companies like formula makers.

FDA Commissioner Marty Makary resigned and Kyle Diamantas will step in as acting commissioner. The resignation comes after speculation and criticism of Makary's performance. Matt Herper has expressed a strongly negative opinion of Makary's tenure.

Marty Makary's departure from the FDA creates uncertainty and may not solve organizational upheaval. The Senate will need to confirm another commissioner while considering other nominees. Makary's exit follows internal criticism and complaints about unpredictable regulatory decisions.

FDA Commissioner Marty Makary resigned amid pressure from anti-abortion groups criticizing his stance on medication abortion access. President Trump praised Makary's work and announced Kyle Diamantas as the acting commissioner. Makary's departure follows recent exits of other senior Trump administration officials.

Marty Makary stepped down as FDA Commissioner due to pressure and rumors about his job security, with Kyle Diamantas taking over as the agency's top food regulator. President Trump acknowledged Makary's difficulties in the role. The transition occurs ahead of Trump's trip to China.

President Trump named Kyle Diamantas as acting FDA commissioner after Marty Makary's resignation. Diamantas is the Deputy FDA Commissioner for Food. Trump announced the change on Truth Social.

Marty Makary is stepping down as FDA Commissioner after a 13-month term marked by controversy and turmoil, and will be replaced by Kyle Diamantas as acting commissioner. The Trump administration will seek to fill three Senate-confirmed health positions. Makary's departure comes amid tensions with the White House and controversies over drug approvals.

Marty Makary is resigning as FDA commissioner after one year, amid reports of President Trump's growing dissatisfaction. He will be replaced by Kyle Diamantas as acting director. The resignation announcement is expected on Tuesday.

Marty Makary resigned as commissioner of the US Food and Drug Administration after a 13-month tenure, frequently drawing ire from the White House, Congress, industry, and the public. Kyle Diamantas will replace him as acting FDA commissioner. The resignation comes after clashes over fruit-flavored vapes with Trump.

Marty Makary is resigning as FDA Commissioner and will be replaced by Kyle Diamantas as acting commissioner. President Donald Trump confirmed the resignation, stating that Makary is a great doctor who will do well. The change occurs amid turmoil at the FDA.